PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biopharmaceutical company focused on developing cell-based therapies for chronic kidney disease, which entered the public markets through a SPAC business combination. The company filed an 8-K with the SEC on January 18, 2022, disclosing a material corporate event tied to its de-SPAC transaction, with the blank-check vehicle having completed its initial public offering in 2021. ProKidney operates within the healthcare and life sciences sector, advancing its lead investigational program in renal autologous cell therapy. For comprehensive filing history, transaction documents, and real-time SPAC status data on DNAC and hundreds of other deals, sign up for full access at SpacDesk.